The Miami Entrepreneur

Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment

Read Time:6 Second

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Nelson Peltz steps down as chair of Wendy’s board, starting a new era for burger chain
Next post ‘I’ve never invested in the stock market’: I’m 64 with $400,000 in CDs and a high-yield savings account. Should I invest in bonds?